Ipamorelin Research Guide: Selective GH Secretagogue, Ghrelin Receptor Biology, and Body Composition Research

By Justin Cartier

See how this fits the wider landscape of growth-hormone and muscle research peptides.

Ipamorelin is a tiny five-amino-acid peptide with exactly one job: telling the body to release its own growth hormone. It binds the ghrelin receptor in the pituitary and sets GH off in natural pulses. But the clever part is what it doesn’t do. No cortisol spike, no prolactin, no surge in appetite, none of the baggage the older peptides dragged along.^[1] This guide covers what it is, how it works, why it’s almost always stacked with CJC-1295, plus dosing, side effects, legal status, and sourcing.

Novo Nordisk built it back in the 1990s. Most research stacks pair it with the GHRH analog CJC-1295, and the logic is honestly neat: the secretagogue fires the GH pulses while CJC-1295 lifts the baseline, so together they mimic natural growth hormone release far better than either does alone. Every key claim below links to its source on PubMed.

Research-use disclaimer: ipamorelin is sold for laboratory research only. It is not a drug or supplement and is not for human use.

What is ipamorelin and how does it work?

It’s a selective growth hormone secretagogue, which is a long way of saying it tells the body to release GH and almost nothing else. Raun and colleagues, in the European Journal of Endocrinology, introduced it in 1998 as the first peptide of its class to release growth hormone without dragging cortisol, prolactin, ACTH, or appetite along for the ride, the way GHRP-2 and GHRP-6 do.^[1] A later rodent study from Venkova and colleagues in the Journal of Pharmacology and Experimental Therapeutics confirmed it binds the ghrelin receptor, GHS-R1a, tightly and behaves as a clean ghrelin mimetic.^[2]

So where does that selectivity actually come from? Honestly, it’s just shape. The five-amino-acid sequence is built to fit the ghrelin receptor and skip the neighbors that drive cortisol and prolactin. That’s the whole advantage over the older GHRPs, and it’s a big one. Want pure GH release with zero stress-hormone or appetite noise fogging up your data? This is the one you grab.

Mechanism: ghrelin receptor and GH release

Here’s the actual chain of events. It binds the ghrelin receptor in the pituitary, that trips a calcium-based signal inside the cell, and out comes growth hormone. But here’s the nice touch: it arrives in pulses that echo the body’s own rhythm, not the flat, steady drip you get from injected GH. Jiménez-Reina and colleagues, in Histology and Histopathology, found it tunes the GH-making somatotroph cells, dialing their output up rather than bulldozing the natural rhythm.^[3]

Stack it with CJC-1295, which raises baseline GH, and the peptide handles the pulse half of the pattern. That’s the standard research combination for body-composition and lean-muscle work.

Body composition and bone effects

Everything on the body-composition side runs through growth hormone, and it’s a modest package: a little lean-mass gain, a little fat loss, and better bone mineral content when you dose it steadily. Johansen and colleagues, in Growth Hormone & IGF Research, reported it increasing longitudinal bone growth in rats in a dose-dependent way.^[4] On the same theme, Svensson’s group in the Journal of Endocrinology showed it and GHRP-6 raising bone mineral content in adult female rats, which props up its use in bone research alongside body-composition endpoints.^[5]

Are the effect sizes modest next to injecting GH outright? Sure they are. But that’s the whole trade. You give up raw magnitude and you get a clean profile back, so the changes show up without the baggage of broad GH replacement, and the downstream IGF-1 rise stays in a gentler range.

Does ipamorelin affect testosterone?

Short answer, no. It leaves testosterone and the reproductive axis completely alone. GHRH analogs can nudge the gonadal axis as a side effect, but this one’s selectivity keeps testosterone, LH, and FSH sitting still at standard doses. And for research where GH is the endpoint, that’s a genuine feature, not a footnote, because gonadal shifts would just muddy the read.

Can ipamorelin be used for weight loss?

Don’t confuse it for a weight-loss peptide, at least not in the GLP-1 sense. The GH-driven fat breakdown it sets off is slow, on the order of 2 to 5 percent over months, with small lean gains alongside. Put that next to semaglutide, around 14.9 percent over 68 weeks, or tirzepatide, around 20.9 percent over 72 weeks, and the gap is obvious. It fits body-recomposition research far better than primary weight-loss endpoints. Paired with tesamorelin in belly-fat work, the combination does push visceral-fat reductions a bit further.

Ipamorelin vs sermorelin vs tesamorelin

All three feed the GH axis, they just knock on different doors. Take sermorelin: it’s a GHRH 1-29 analog that lifts baseline GH from the pituitary, but the half-life is short, so you’re dosing every evening. Tesamorelin does the same baseline-raising job as a stabilized GHRH 1-44 analog, except it lasts longer, and it’s the only one here with a real FDA approval, for HIV lipodystrophy. Ipamorelin is the odd one out here: a ghrelin-receptor agonist working a completely different receptor from the other two, firing pulse GH release with that hallmark selectivity and no cortisol or prolactin tail. That receptor difference is what makes stacks tick. Pair it with sermorelin or tesamorelin and you hit two separate receptors, so the effects add up, whereas pairing it with GHRP-6 hits the same receptor and adds almost nothing. CJC-1295 plus ipamorelin stays the most common research stack.

Dosage and administration

Research protocols run 100 to 300 micrograms per dose under the skin, two to three times a day. A bedtime dose lines up with the body’s natural night-time GH pulse. The peptide ships as a lyophilized powder and gets reconstituted with bacteriostatic water. The half-life is short, roughly 2 hours, so steady GH-pulse activity means dosing several times a day. In the combined pen, a common split is 100 micrograms of ipamorelin plus 100 micrograms of CJC-1295 per shot.

Side effects and downsides of ipamorelin

That selective profile keeps the side effects quiet next to the older GHRPs. What actually turns up in research protocols is pretty tame: a little injection-site irritation, the odd brief bout of water retention in line with low-dose GH, and a rare mild headache. The bigger story is the absence, no cortisol rise, no prolactin rise, no appetite kick, which were the main downsides of GHRP-6 and GHRP-2. The genuine drawbacks are practical: that short half-life forcing several doses a day, and effect sizes modest enough that measurable body-composition change takes months of steady use.

Why did the FDA ban ipamorelin?

It wasn’t a ban in the literal sense, so let’s clear that up. In 2023 the FDA added it to the 503A “do not compound” list, alongside several other GH-axis peptides. That stops US compounding pharmacies from preparing it for patient use, but it didn’t pull an approved product off shelves, because it was never FDA-approved as a finished drug in the first place. Novo Nordisk halted development before filing. Research-grade material stays available to Canadian and US labs under research-use-only labels. It is, however, on the World Anti-Doping Agency banned list.

Is ipamorelin legal to buy?

Yes, in Canada and the United States as a research chemical sold under research-use-only labels. Neither Health Canada nor the FDA has cleared it as a finished drug. The 503A “do not compound” listing limits pharmacy compounding but doesn’t touch research-chemical sales. And for competitive athletes, note that it sits on the WADA banned list.

Research-grade ipamorelin sells legally in Canada as a research chemical, a status our guide to the Canadian legal framework for buying peptides explains in full.

Sourcing for research

Ipamorelin’s whole value is clean, selective binding to a single receptor, GHS-R1a, so its exact identity has to be confirmed or your GH-release and receptor-binding data drift. A truncated chain or a wrong-sequence batch can still latch onto the ghrelin receptor, just with different affinity, which quietly skews potency and selectivity readouts before you notice. So verify the molecule before you trust the numbers. Ask for mass spectrometry matching the pentapeptide’s expected weight near 711 Da, HPLC purity of 98 percent or higher to rule out close-sequence impurities, and a lot-specific report from an independent testing facility. For any in-vivo or cell-culture GH work, add endotoxin and sterility testing.

Reviv Peptides supplies research-grade ipamorelin and the CJC-1295 + ipamorelin blend. View the Ipamorelin 10mg product page, or view the CJC-1295 + Ipamorelin Blend.

Ipamorelin questions

What does ipamorelin do to the body?

It binds the ghrelin receptor in the pituitary and triggers GH in natural pulses. The downstream effects are modest lean-mass gain, modest fat loss, and better bone mineral content with steady dosing. Its selective binding means no cortisol, prolactin, or appetite effects.

What are the downsides or side effects of ipamorelin?

Minimal: mild injection-site irritation, occasional brief water retention, the rare mild headache. The practical downsides are the short half-life that needs multi-daily dosing and modest effect sizes that need months of steady use for measurable change.

Why did the FDA ban ipamorelin?

It wasn’t banned outright. It was added to the FDA 503A “do not compound” list in 2023, which limits compounding-pharmacy preparation. It was never FDA-approved as a finished drug, and research-grade material stays legal in Canada and the United States under research-use-only labels.

Does ipamorelin affect testosterone?

No. Its receptor selectivity keeps it off the reproductive axis, so testosterone, LH, and FSH stay unchanged at standard research doses.

What is the correct ipamorelin dosage?

Research protocols use 100 to 300 micrograms per dose under the skin, two to three times a day. A bedtime dose matches the natural GH pulse. The half-life is short, about 2 hours, so multi-daily dosing keeps activity steady.

Key data point: in its founding study, the peptide released growth hormone as potently as the older GHRPs but, uniquely for its class, did so without raising cortisol, prolactin, ACTH, or appetite, which is what earned it the “first selective GH secretagogue” label.^[1]

Summary

So where does it leave you? Ipamorelin is the most selective growth hormone secretagogue in the research peptide category, and it hits the ghrelin receptor in the pituitary clean, without the off-target cortisol, prolactin, or appetite effects that dog the older GHRPs. It’s most often paired with the GHRH analog CJC-1295 for combined pulse-and-baseline GH coverage in body-composition work. Its effects on lean mass, fat, and bone are modest but reliable with steady dosing. It isn’t FDA-approved as a finished drug, and it landed on the FDA 503A “do not compound” list in 2023, though research-grade material stays legal in Canada and the United States under research-use-only labels. And it’s on the WADA banned list.

Sources: [1] Ipamorelin, the first selective GH secretagogue, PubMed. [2] Ipamorelin, a ghrelin-receptor mimetic (efficacy in a rodent model), PubMed. [3] Ipamorelin and the somatotroph GH response, PubMed. [4] Ipamorelin induces longitudinal bone growth in rats, PubMed. [5] Ipamorelin and GHRP-6 increase bone mineral content in rats, PubMed.

Justin Cartier

The Reviv Peptides Research Team is a collective of science writers and researchers dedicated to producing evidence-based, peer-reviewed-grade content about research peptides. Our work focuses on molecular mechanisms, receptor pharmacology, and preclinical data — including GLP-1/GIP/glucagon incretin biology, growth hormone axis peptides (GHRH analogs and ghrelin-receptor secretagogues), mitochondrial-derived peptides (MOTS-c, SS-31), tissue-repair peptides (BPC-157, TB-500, GHK-Cu), and nootropic peptides (Semax, Selank). All content is written in a strict preclinical/laboratory context; none of our editorial material is intended as medical advice. Every guide is reviewed for scientific accuracy against published peer-reviewed literature.